CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. REGULATORY INTELLIGENCE: INDUSTRY’S BEST PRACTICE OMICS 5 th International Pharmaceutical.

Slides:



Advertisements
Similar presentations
Evaluation at NRCan: Information for Program Managers Strategic Evaluation Division Science & Policy Integration July 2012.
Advertisements

Module N° 4 – ICAO SSP framework
Session No. 4 Implementing the State’s Safety Programme Implementing Service Providers SMS
ONS Research Data Access Strategy AGENDA Background and context Confidentiality The Strategy.
A BPM Framework for KPI-Driven Performance Management
DG Enterprise and Industry Approach on Combating Counterfeit Medicines Council of Europe Conference “Europe against Counterfeit Medicines” Session: Key.
Achieve Benefit from IT Projects. Aim This presentation is prepared to support and give a general overview of the ‘How to Achieve Benefits from IT Projects’
Medsafe – GMP update / release for supply / communicating quality issues Derek Fitzgerald Manager, Compliance Management 11 July 2013 RACI Pharmaceutical.
AUDIT COMMITTEE FORUM TM ACF Roundtable IT Governance – what does it mean to you as an audit committee member July 2010 The AUDIT COMMITTEE FORUM TM is.
MODULE 3 THE ENVIRONMENTAL PRINCIPLES Session 2: Principle 8
INTEGRATING BENEFICIARY FEEDBACK INTO EVALUATION- A STRUCTURED APPROACH Presentation to UKES Conference May 2015 Theme: Theory and practice of inclusion.
Unit Slides by UK Versity.  Unit aims:  This unit aims to help the learner with an opportunity to develop their project management and research skills.
Certified Business Process Professional (CBPP®)
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Impact Measurement and You Understanding Impact Measurement, Practical Tools, Key Questions.
A Review ISO 9001:2015 Draft What’s Important to Know Now
Regulatory requirements and benefits converting to Continued Process Verification.
Session No. 4 Implementing Service Providers SMS Implementing the State’s Safety Programme SMS Senior Management Workshop Rome, 21 May 2007.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
The economic regulation of gas processing services Key issues and initial thoughts Ofgem presentation 18 June 2007.
Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
Web Analytics and Social Media Monitoring CAM Diploma in Digital Marketing (Metrics and Analytics) Assignment Briefing December 2013 & March 2014 Papers.
ISO 9001:2015 Revision overview - General users
Developing Enterprise Architecture
Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.
1 Module 4: Designing Performance Indicators for Environmental Compliance and Enforcement Programs.
Community Services Programme Strand 1 & 3 Business Planning Re-contracting April 2014.
Regulatory Transparency and Interaction with the Government Dr. Konstantin Petrov Head of Section, Policy and Regulation.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Slide 1 D2.TCS.CL5.04. Subject Elements This unit comprises five Elements: 1.Define the need for tourism product research 2.Develop the research to be.
Professional Certificate – Managing Public Accounts Committees Ian “Ren” Rennie.
INTRODUCTION TO RA.
Quote for today “Sometimes the questions are complicated and the answers are simple” - ?? ????? “Sometimes the questions are complicated and the answers.
Management & Development of Complex Projects Course Code - 706
INNOWATER Introduction to Business Proposition Toolkit July 2013.
Module N° 8 – SSP implementation plan. SSP – A structured approach Module 2 Basic safety management concepts Module 2 Basic safety management concepts.
Comcare Compliance Assistance Section Presents Incident Notification.
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. THE PRACTICE OF REGULATORY INTELLIGENCE: CASE STUDIES OMICS 5 th International Pharmaceutical.
INTERNATIONAL LABOUR ORGANIZATION Conditions of Work and Employment Programme (TRAVAIL) 2012 Module 13: Assessing Maternity Protection in practice Maternity.
Alaska Staff Development Network – Follow-Up Webinar Emerging Trends and issues in Teacher Evaluation: Implications for Alaska April 17, :45 – 5:15.
© 2011 Underwriters Laboratories Inc. All rights reserved. This document may not be reproduced or distributed without authorization. ASSET Safety Management.
Training Course on “Training of Trainers from the Greater Mekong Sub- Region on Decentralized Education Planning in the Context of Public Sector Management.
Digital Preservation Coalition Supporting Digital Preservation NOF-digi Preservation Workshop Senior Managers’ Brief Maggie Jones DPC Co-ordinator
Towards an Industry Advisory Group An Open Round-Table Conversation 19 May 2009 Do not copy or reproduce without express written permission of Foresight.
Principles of Marketing Lecture-11. Summary of Lecture-10.
The Commission's Impact Assessment system 18 September 2014 María Dolores Montesinos Impact Assessment unit Secretariat General 1.
Copyright  2005 McGraw-Hill Australia Pty Ltd PPTs t/a Australian Human Resources Management by Jeremy Seward and Tim Dein Slides prepared by Michelle.
Professional Certificate in Electoral Processes Understanding and Demonstrating Assessment Criteria Facilitator: Tony Cash.
Advisory Committee for Diversity in the Digital Age.
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
Consultant Advance Research Team. Outline UNDERSTANDING M&E DATA NEEDS PEOPLE, PARTNERSHIP AND PLANNING 1.Organizational structures with HIV M&E functions.
The new EC impact assessment: what for? EUROPEAN TRADE UNION CONFEDERATION Sophie Dupressoir.
Developing a programme for the implementation of the 2008 SNA and supporting statistics Seminar on Developing a programme for the implementation of the.
Rethinking a Responsibility In India: a review of Pharmaceutical & Private Healthcare sectors BUSINESSES’ CONTRIBUTION TOWARDS GROWTH & SUSTAINABLE DEVELOPMENT.
Guidance document on Water and Climate adaptation Jos G. Timmerman Rijkswaterstaat Centre for Water Management.
Fundamentals of Governance: Parliament and Government Understanding and Demonstrating Assessment Criteria Facilitator: Tony Cash.
Results orientation: audit perspective Jiri Plecity, Head of Unit H1, Relations with Control Authorities, Legal Procedures, Audit of Direct Management.
Overview PRINCE Hogeschool Rotterdam. 2 Project definition  A project is a temporary organization that is created for the purpose of delivering.
Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,
KENYA REVENUE AUTHORITY BUSINESS INTELLIGENCE OFFICE PRESENTATION INVESTIGATION & ENFORCEMENT DEPARTMENT SYMON YATICH 29 TH - 31 ST AUGUST 2012.
Alex Ezrakhovich Process Approach for an Integrated Management System Change driven.
How to successfully Implement and Leverage the Regulatory Intelligence Function Marianne Koehne EU RI Network Group; Global RI Manager Boehringer Ingelheim.
Fostering Antimicrobial Stewardship in Animals: Overview of FDA Activities William Flynn, DVM, MS Deputy Director for Science Policy Center for Veterinary.
Partnering with Regulatory Intelligence Speakers: Amy Grant, MS Viropharma Incorporated Penny Levin, MS Cephalon Danielle Ziernicki, Pharm.D. Johnson &
1 From Regulatory Intelligence to Compliance Debbie Henderson Head, Global Regulatory Policy EU Ring May 13, 2014.
Linda Bowen Regulatory Intelligence sanofi-aventis
Communicating Actionable Regulatory Intelligence João Duarte Regulatory Intelligence Strategy Leader H. Lundbeck A/S.
Proposal and Company Information Document CONTENT About Indagatio Research Our Research Offerings Why Indagatio Research Our Work Process Project Snapshot.
FDA Guidance for Industry and FDA Staff Summary of Public Notification of Emerging Postmarket Medical Device Signals (“Emerging Signals”) Effective: December.
Presentation transcript:

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. REGULATORY INTELLIGENCE: INDUSTRY’S BEST PRACTICE OMICS 5 th International Pharmaceutical Regulatory Affairs, August 2015, Orlando, Florida, USA Presented by: Mariam Aslam

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / AGENDA Introduction Definition of Regulatory Intelligence (RI) Analysis of Definition Summary 2

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / INTRODUCTION Regulatory Intelligence (RI or reg intel) is likely to have been practiced in some way or other from when regulations first came in to existence. In the recent years, RI has become more of a phenomenon in the pharmaceutical regulatory sector. Although the brilliance of this concept is still evolving, two definitions have been created for RI by: - the Drug Information Association’s Regulatory Intelligence Network Group (DIA RING) - the EU Regulatory Intelligence Group (EU RING). 3

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ‘The act of gathering and analyzing publicly available regulatory information. This includes communicating the implications of that information, and monitoring the current regulatory environment for opportunities to shape future regulations, guidance, policy, and legislation.’ ‘Regulatory intelligence is the act of processing targeted information and data from multiple sources, analyzing the data in its relevant context and generating a meaningful output – e.g. outlining risks and opportunities – to the regulatory strategy. The process is driven by business needs and linked to decisions and actions.' THE DIA RING DEFINITION 4 DEFINITION OF REGULATORY INTELLIGENCE (RI) THE EU RING DEFINITION

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF DIA RING DEFINITION THE NEXT SLIDES WILL DISCUSS THE DEFINITION IN FRAGMENTS. 5

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF DIA RING DEFINITION The act of gathering and analyzing publicly available regulatory information. This includes communicating the implications of that information, and monitoring the current regulatory environment for opportunities to shape future regulations, guidance, policy, and legislation.’ 6

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF DIA RING DEFINITION The act of gathering and analyzing publicly available regulatory information. Publicly available regulatory information: - Regulatory Authority websites (e.g. EMA, FDA, TGA and NCA) - Regulatory Journals/Newsletters - Conferences/meetings - Consultants/colleagues - Groups on LinkedIn - Executing a gap analysis (what data is available, what is missing) - Conducting Regulatory surveys (asking a serious of regulatory implication questions) 7

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF DIA RING DEFINITION The act of gathering and analyzing publicly available regulatory information. This includes communicating the implications of that information, and monitoring the current regulatory environment for opportunities to shape future regulations, guidance, policy, and legislation.’ 8

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF DIA RING DEFINITION This includes communicating the implications of that information, How and who do you communicate with. Consider: - Gap analysis (what data is available, what is missing) - Conducting Regulatory surveys (asking a serious of regulatory implication questions) - Business functions such as marketing, quality, supply chain 9

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF DIA RING DEFINITION The act of gathering and analyzing publicly available regulatory information. This includes communicating the implications of that information, and monitoring the current regulatory environment for opportunities to shape future regulations, guidance, policy, and legislation.’ 10

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF DIA RING DEFINITION monitoring the current regulatory environment for opportunities to shape future regulations, guidance, policy, and legislation.’ How can you achieve this: Accomplished with first part of definition (…gathering and analyzing publicly available regulatory information…) Access to Regulatory Authorities public consultation Challenge current guidelines, have a better course of action with justification; communicate with RA Keep abreast of new regulations and the impact they can have on existing directives. 11

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF EU RING DEFINITION THE NEXT SLIDES WILL DISCUSS THE DEFINITION IN FRAGMENTS. 12

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF EU RING DEFINITION Regulatory intelligence is the act of processing targeted information and data from multiple sources, analyzing the data in its relevant context and generating a meaningful output – e.g. outlining risks and opportunities – to the regulatory strategy. The process is driven by business needs and linked to decisions and actions. 13

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF EU RING DEFINITION Regulatory intelligence is the act of processing targeted information and data from multiple sources, More specific than first leg DIA RING (…gathering and analyzing publicly available regulatory information…) Targeted information & data: Seeking specific information for the purpose of your RI, e.g. variation to change the formulation of a drug product that are licenced only in the Asia Pacific (APAC) markets. 14

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF EU RING DEFINITION Regulatory intelligence is the act of processing targeted information and data from multiple sources, Data from multiple sources: - Regulatory Authority websites (e.g. EMA, FDA, TGA and NCA) - Regulatory Journals/Newsletters - Conferences/meetings - Consultants/colleagues - Groups on LinkedIn - Executing a gap analysis (what data is available, what is missing) - Conducting Regulatory surveys (asking a serious of regulatory implication questions) 15

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF EU RING DEFINITION Regulatory intelligence is the act of processing targeted information and data from multiple sources, analyzing the data in its relevant context and generating a meaningful output – e.g. outlining risks and opportunities – to the regulatory strategy. The process is driven by business needs and linked to decisions and actions. 16

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF EU RING DEFINITION analyzing the data in its relevant context and generating a meaningful output – e.g. outlining risks and opportunities – to the regulatory strategy. For example, data for changing the formulation of your drug product. How can the data be analysed to prepare a regulatory strategy & risk analysis to make this change. Consider: - Markets impacted - Type of regulatory change - What documentation are required for submission package - Timeframe for approval - When can the change be implemented - Commercial, Quality and Supply Chain impact 17

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF EU RING DEFINITION Regulatory intelligence is the act of processing targeted information and data from multiple sources, analyzing the data in its relevant context and generating a meaningful output – e.g. outlining risks and opportunities – to the regulatory strategy. The process is driven by business needs and linked to decisions and actions. 18

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / ANALYSIS OF EU RING DEFINITION The process is driven by business needs and linked to decisions and actions. Taking the previous example, changing the formulation of a drug product. What are the possible business needs to drive the RI process? - Improve quality of drug - Reduce cost - Increase productivity 19

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / SUMMARY However you interpret these definitions, RI key aspect is applying the acquired knowledge from drug discovery to post approval. A vast amount of years and cost is invested in getting the drug on the market. Then when it gets to the market, what happens next? This is when the importance of RI ensures the best regulatory strategy so that your drug’s safety, quality and efficacy is maintained during its lifecycle. 20

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / SUMMARY RI PROCESS Regulatory Intelligence Data Collection Data Analysis Risk assessment Regulatory Strategy Communication Application 21

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / CONTACT DETAILS 22

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / THANK YOU CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. / 23